HighTower Advisors LLC Sells 20,000 Shares of iRadimed Corporation $IRMD

HighTower Advisors LLC cut its holdings in shares of iRadimed Corporation (NASDAQ:IRMD) by 33.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,361 shares of the medical equipment provider’s stock after selling 20,000 shares during the quarter. HighTower Advisors LLC owned approximately 0.32% of iRadimed worth $2,872,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of IRMD. SG Americas Securities LLC raised its position in shares of iRadimed by 408.8% in the second quarter. SG Americas Securities LLC now owns 36,516 shares of the medical equipment provider’s stock valued at $2,183,000 after purchasing an additional 29,339 shares during the period. Geode Capital Management LLC raised its holdings in iRadimed by 6.5% during the 2nd quarter. Geode Capital Management LLC now owns 261,386 shares of the medical equipment provider’s stock valued at $15,630,000 after acquiring an additional 15,996 shares during the period. Ranger Investment Management L.P. lifted its position in shares of iRadimed by 7.4% during the second quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock worth $12,845,000 after acquiring an additional 14,730 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of iRadimed by 8,568.5% during the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock worth $591,000 after acquiring an additional 11,139 shares in the last quarter. Finally, Grandeur Peak Global Advisors LLC boosted its holdings in shares of iRadimed by 96.6% in the second quarter. Grandeur Peak Global Advisors LLC now owns 22,165 shares of the medical equipment provider’s stock worth $1,325,000 after acquiring an additional 10,892 shares during the period. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Trading Up 1.9%

IRMD stock opened at $102.42 on Friday. The company’s 50 day moving average is $99.35 and its 200 day moving average is $86.20. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of 58.53 and a beta of 1.11. iRadimed Corporation has a 1-year low of $47.48 and a 1-year high of $107.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. The business had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.85%. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, sell-side analysts forecast that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Monday, February 23rd will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.8%. This is an increase from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date of this dividend is Monday, February 23rd. iRadimed’s dividend payout ratio is presently 45.71%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Roth Mkm reiterated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research note on Tuesday, February 10th. Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research note on Wednesday, February 11th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, iRadimed has a consensus rating of “Moderate Buy” and an average price target of $120.00.

Insider Transactions at iRadimed

In other news, CFO John Glenn sold 15,000 shares of the stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the transaction, the chief financial officer directly owned 7,362 shares in the company, valued at approximately $716,248.98. This represents a 67.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $95.43, for a total value of $477,150.00. Following the completion of the sale, the chief executive officer owned 2,297,500 shares of the company’s stock, valued at $219,250,425. The trade was a 0.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,000 shares of company stock valued at $4,408,150 over the last quarter. Company insiders own 36.80% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.